Trials of a daily obesity pill showed patients lost about 12% of their body weight over 72 weeks.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 percent of their body weight.

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs.

People taking the new wonder drug orforglipron lost an average of 12.4 per cent of their body weight after 72 weeks and benefited from reductions in bad cholesterol, blood fats…

Eli Lilly’s orforglipron could offer needle-free alternative to weight-loss jabs at lower cost

Trials of a daily obesity pill showed patients lost about 12% of their body weight over 72 weeks.

Results of study suggest orforglipron could be a simpler, cheaper alternative to injections

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount of weight, the company said.